In a continued effort to combat lung cancer, the Lung Cancer Foundation of America (LCFA) and the International Association for the Study of Lung Cancer (IASLC) have awarded $400,000 to two promising early-career researchers. The funding, announced during Lung Cancer Awareness Month, aims to address the critical gap in resources that often stalls innovative research ideas. By providing this support, the organizations hope to accelerate breakthroughs that could lead to earlier detection and more effective treatments for lung cancer, which claims a life in the United States every 4.2 minutes.
The two funded projects focus on pressing challenges: detecting lung cancer earlier and preventing drug resistance. Dr. Jared Mayers of Fred Hutch Cancer Center is investigating the role of lung microbiome in cancer development, developing sensitive techniques to study these bacteria that were previously difficult to analyze. His work could reveal new strategies for prevention. Dr. Jaime L. Schneider of Dana-Farber Cancer Institute is decoding how lung cancer cells adapt to treatments, aiming to identify vulnerabilities that can be exploited to design more durable therapies. Both projects hold promise for improving patient outcomes.
The Early Career Researcher (ECR) grant program is designed to provide emerging scientists with the initial funding needed to secure major independent research awards. According to Kim Norris, co-founder and president of LCFA, “Supporting early-career investigators is not just a strategic priority. It is a necessity for the future of oncology.” The program has demonstrated a remarkable multiplier effect, with a current 13X return on investment. To date, LCFA has awarded 25 grants totaling $4.6 million, which has leveraged over $50 million in additional research funding from other organizations.
Dr. Mayers expressed his motivation: “We don't get new drugs, we don't get new therapies, we don't get longer lives, better quality lives, more time with family unless we invest in the upfront groundwork.” Dr. Schneider, drawn to thoracic oncology by the array of new drugs changing patient lives, aims to find ways to keep cancer from adapting. The LCFA and IASLC invite the community to learn more about these researchers through their Meet the Researcher profiles and video insights.
This $400,000 investment underscores the commitment of both organizations to accelerate discovery and bring innovative ideas from the lab to the clinic. For more resources and information about lung cancer, visit lcfamerica.org.
